Navigation Links
Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
Date:9/17/2008

DUBLIN, Calif., Sept. 17 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) has been awarded a $625,000 contract under the inaugural US Army Commercialization Pilot Program for the development of a Universal Sample Preparation Module (USPM). The Commercialization Pilot Program is a new program to assist SBIR firms that have Phase II projects that meet high priority Army requirements in transitioning to commercial products.

MBI's project will develop a Universal Sample Preparation Module that will automatically purify DNA from pathogen targets contained in complex matrices to provide samples for various downstream DoD-sponsored analytical platforms. The USPM will enable front-end sample preparation with high specificity for rapid detection, identification, and diagnosis of biological threat agents and will be applicable to detecting pathogens for molecular diagnostics. Using MBI's Microscale On-chip Valves (MOV(TM)) technology, the USPM will integrate multiple sample processing steps in a small, universal sample preparation module that integrates immunomagnetic separation capture with lysis and nucleic acid purification.

"Easy-to-use sample preparation, under field conditions, has always been a major obstacle to deploying back end pathogen detection and identification devices as well as molecular diagnostics devices. The USPM will greatly simplify this process and improve detection sensitivity," said Dr. Joanne Horn, Project Manager, heading the USPM development at MBI.

About Microchip Biotechnologies Inc.

Microchip Biotechnologies, Inc. (MBI) is developing the Apollo next-generation fluidics platform for Life Sciences, Applied Sciences, and Diagnostics markets. The Apollo platform incorporates MBI's proprietary BeadStorm(TM). bead-based sample preparation devices and patented "Microscale On-chip Valves" (MOV(TM)) valves, pumps, and routers on microchips to integrate, automate, and simplify workflows. The Company's first product, the Apollo 100, integrates advanced microfluidic sample preparation to reduce the cost of DNA sequencing. MBI is now adding analytical capabilities to Apollo platform to create breakthrough sample-to-answer devices for biodefense, DNA-based forensics and human identity (HID), and molecular diagnostics applications. MBI is privately held and based in Dublin, California; more details can be found on the Company's website: http://www.microchipbiotech.com.


'/>"/>
SOURCE Microchip Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. Quick microchip test for dangerous antibiotic resistant bacteria
3. Team develops energy-efficient microchip
4. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
5. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
6. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
7. Melting defects could lead to smaller, more powerful microchips
8. MIT reports finer lines for microchips
9. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
10. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
11. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):